The patent for semaglutide, the drug used in major weight-loss medications like Wegovy and Ozempic has expired. The end of the patent — held by Danish pharmaceutical giant Novo Nordisk — opens the door to affordable generic versions in the country. The World’s Host Carolyn Beeler learns more about the potential impact from Dr. Rahul Baxi, a diabetologist in Mumbai.
The story you just read is not locked behind a paywall because listeners and readers like you generously support our nonprofit newsroom. Now more than ever, we need your help to support our global reporting work and power the future of The World. Can we count on you?